IDiyas

For the Inventor, By the Inventor

Montreal, Canada

Yves Ducharme

USPTO Granted Patents = 29



Average Co-Inventor Count = 6.9

ph-index = 12

Forward Citations = 1,214(Granted Patents)


Location History:

  • Montreal, CA (1993 - 2011)
  • Brookline, MA (US) (2016 - 2017)

Company Filing History:

goldMedal20 out of 212 
 
Merck Frosst Canada, Inc.
 patents
silverMedal6 out of 76 
 
Merck Frosst Canada & Co.
 patents
bronzeMedal3 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
4. 2 out of 40 
 
Merck Canada Inc.
 patents
where one patent can have more than one assignee

Years Active: 1993-2017

Loading Chart...
Loading Chart...
Loading Chart...
29 patents (USPTO):
1. 9586931 - Triazolyl derivatives as Syk inhibitors (2017-03-07),
2. 9242984 - Pyrazolyl derivatives as Syk inhibitors (2016-01-26),
3. 7960409 - Pharmaceutical phenylquinoline and chromen-2-one triazole compounds (2011-06-14),
4. 7943649 - 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors (2011-05-17),
5. 7442716 - 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors (2008-10-28),
6. 6841564 - Tri-aryl-substituted-ethane PDE4 inhibitors (2005-01-11),
7. 6639077 - Tri-aryl-substituted-ethane PDE4 inhibitors (2003-10-28),
8. 6486194 - Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases (2002-11-26),
9. 6448274 - Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor (2002-09-10),
10. 6399636 - Tri-aryl-substituted-ethane PDE4 inhibitors (2002-06-04),
11. 6316472 - Heterosubstituted pyridine derivatives as PDE 4 inhibitors (2001-11-13),
12. 6200993 - Heterosubstituted pyridine derivatives as PDE4 inhibitors (2001-03-13),
13. 5840746 - Use of inhibitors of cyclooxygenase in the treatment of (1998-11-24),
14. 5710170 - Tri-aryl ethane derivatives as PDE IV inhibitors (1998-01-20),
15. 5710160 - Diphenyl pyridyl ethane derivatives as PDE IV inhibitors (1998-01-20),

Title: Yves Ducharme: Innovator in Spleen Tyrosine Kinase Inhibition

Introduction: Yves Ducharme, based in Montreal, Canada, is a prolific inventor known for his significant contributions to the field of medicinal chemistry. With an impressive portfolio of 29 patents, Ducharme has dedicated his career to developing novel compounds aimed at treating various diseases.

Latest Patents: Among Ducharme's latest innovations are two notable patents focusing on the inhibition of spleen tyrosine kinase (Syk). The first, titled "Triazolyl Derivatives as Syk Inhibitors," presents triazole derivatives that demonstrate potent inhibition of Syk, proving useful in treating diseases like asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, and cancer. The second patent, "Pyrazolyl Derivatives as Syk Inhibitors," showcases novel pyrazole derivatives with similar therapeutic potential, further solidifying his contributions to enzyme-targeted therapies.

Career Highlights: Throughout his career, Ducharme has been affiliated with prominent companies in the pharmaceutical industry. He worked extensively at Merck Frosst Canada, Inc. and Merck Frosst Canada & Co., where he played a crucial role in advancing research initiatives and pharmaceutical development.

Collaborations: Ducharme's work has been enriched by collaborations with talented colleagues, including Pierre A. Hamel and Daniel Guay. Their combined expertise has fostered innovation and contributed to the successful development of groundbreaking therapies.

Conclusion: Yves Ducharme is a distinguished figure in the realm of medicinal chemistry, with a strong focus on Syk inhibitors. His patents not only reflect his innovative spirit but also aim to provide therapeutic solutions for complex diseases. Through his collaborations and work with established pharmaceutical companies, Ducharme continues to make a significant impact on healthcare and patient well-being.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…